HC Wainwright Reiterates Buy Rating on SLN
HC Wainwright maintains its optimistic view on SLN, setting a $75 price target, a 1017.73% upside from the current price.
Key Points
- On June 17, 2026, HC Wainwright reiterated its buy rating on SLN, maintaining a price target of $75.
- HC Wainwright's $75 price target implies 1017.73% upside from Silence Therapeutics plc's ($SLN) current $6.71 share price.
- SLN shares traded at $6.71, with significant institutional interest from funds like Nantahala Capital and Citadel Advisors.
- Insider Richard Ian Griffiths made multiple purchases of SLN shares in 2025, reflecting ongoing insider activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright reiterated its buy rating for SLN on June 17, 2026, keeping the price target steady at $75. Analyst Patrick R. Trucchio remains bullish on the stock, suggesting significant upside potential from its current trading price of $6.71.
Other Institutional Activity in SLN
Several institutional investors have shown interest in SLN. Nantahala Capital Management, LLC increased its holdings by 604,304 shares, bringing its total to 2,146,731 shares valued at approximately $11.31 million. Citadel Advisors LLC made a notable addition of 990,746 shares, resulting in a total of 1,234,807 shares worth about $6.51 million. Meanwhile, TCG Crossover Management, LLC and Siren, L.L.C. held steady, with no changes to their respective positions of 3,033,560 and 2,911,438 shares.
Silence Therapeutics plc Stock Down 50.0%
Shares of SLN are currently trading at $6.71. The company has attracted attention from various institutional investors, suggesting a sense of stability and interest in its future prospects. The stock's performance and analyst ratings indicate it is on the radar for potential growth.
Insider Buying and Selling at Silence Therapeutics plc
Richard Ian Griffiths, an insider at SLN, made several purchases of the company's stock in 2025. On October 27, he bought 2,000 shares multiple times, and on August 3, he acquired 20,000 shares twice. These transactions, although not part of a pre-planned trading scheme, indicate his continued confidence in SLN.
Analysts Set New Price Targets
On June 17, 2026, HC Wainwright & Co. reiterated its buy rating on SLN with a $75 price target. This follows similar reiterations on March 13, 2026, and September 16, 2025. Other analyst firms have varied views: Chardan Capital maintained a buy rating with a $35 target, while Goldman Sachs maintained a sell rating with a $3 target.
Bottom Line
HC Wainwright's consistent buy rating and high price target reflect strong confidence in SLN's potential. The stock is trading well below this target, presenting a notable gap. Institutional and insider activities further underscore the interest in SLN. As always, remember that analyst ratings and institutional filings are backward-looking and should be considered as part of a broader investment strategy.
Get Silence Therapeutics plc alerts
New 13F filings, insider trades, and analyst moves on $SLN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.